These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 22129044

  • 1. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
    Huijts CM, Santegoets SJ, van den Eertwegh AJ, Pijpers LS, Haanen JB, de Gruijl TD, Verheul HM, van der Vliet HJ.
    BMC Cancer; 2011 Nov 30; 11():505. PubMed ID: 22129044
    [Abstract] [Full Text] [Related]

  • 2. Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
    Werter IM, Huijts CM, Lougheed SM, Hamberg P, Polee MB, Tascilar M, Los M, Haanen JBAG, Helgason HH, Verheul HM, de Gruijl TD, van der Vliet HJ, Dutch WIN-O Consortium.
    Cancer Immunol Immunother; 2019 May 30; 68(5):787-798. PubMed ID: 30756132
    [Abstract] [Full Text] [Related]

  • 3. Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.
    Huijts CM, Werter IM, Lougheed SM, Goedegebuure RS, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ, Dutch WIN-O Consortium.
    Cancer Immunol Immunother; 2019 Feb 30; 68(2):319-329. PubMed ID: 30413837
    [Abstract] [Full Text] [Related]

  • 4. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ.
    Clin Genitourin Cancer; 2014 Aug 30; 12(4):241-50. PubMed ID: 24685058
    [Abstract] [Full Text] [Related]

  • 5. The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.
    Huijts CM, Lougheed SM, Bodalal Z, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ, Dutch WIN-O Consortium.
    Cancer Immunol Immunother; 2019 Mar 30; 68(3):503-515. PubMed ID: 30652208
    [Abstract] [Full Text] [Related]

  • 6. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, Guo J.
    BMC Cancer; 2014 May 28; 14():376. PubMed ID: 24886512
    [Abstract] [Full Text] [Related]

  • 7. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC, Barbeau S, McMillian A, Srinivas S.
    Clin Genitourin Cancer; 2013 Jun 28; 11(2):100-6. PubMed ID: 23352238
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
    Guo J, Huang Y, Zhang X, Zhou F, Sun Y, Qin S, Ye Z, Wang H, Jappe A, Straub P, Pirotta N, Gogov S.
    BMC Cancer; 2013 Mar 21; 13():136. PubMed ID: 23514360
    [Abstract] [Full Text] [Related]

  • 9. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R.
    Expert Opin Pharmacother; 2011 May 21; 12(7):1143-55. PubMed ID: 21470068
    [Abstract] [Full Text] [Related]

  • 10. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK.
    Clin Genitourin Cancer; 2014 Oct 21; 12(5):335-40. PubMed ID: 24787966
    [Abstract] [Full Text] [Related]

  • 11. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Vogelzang NJ.
    Curr Med Res Opin; 2014 Oct 21; 30(10):2041-50. PubMed ID: 24983741
    [Abstract] [Full Text] [Related]

  • 12. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I, Wimalasingham A, Burke W, Sarker SJ, Hussain S, Ralph C.
    Eur Urol; 2016 Mar 21; 69(3):450-6. PubMed ID: 26364551
    [Abstract] [Full Text] [Related]

  • 13. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A, Medioni J, Scotte F, Schmidinger M, Kramer G, Combe P, Gornadha Y, Elaidi R, Oudard S.
    Oncology; 2013 Mar 21; 85(1):8-13. PubMed ID: 23797151
    [Abstract] [Full Text] [Related]

  • 14. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I, REACT Study Group.
    Eur J Cancer; 2012 Feb 21; 48(3):324-32. PubMed ID: 21803569
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
    Porta C, Calvo E, Climent MA, Vaishampayan U, Osanto S, Ravaud A, Bracarda S, Hutson TE, Escudier B, Grünwald V, Kim D, Panneerselvam A, Anak O, Motzer RJ.
    Eur Urol; 2012 Apr 21; 61(4):826-33. PubMed ID: 22297244
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R, Obara W, Matsuura T, Kato Y, Iwasaki K, Fujioka T.
    Jpn J Clin Oncol; 2014 May 21; 44(5):479-85. PubMed ID: 24688083
    [Abstract] [Full Text] [Related]

  • 18. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Ravaud A, Kim D, Panneerselvam A, Anak O, Figlin RA.
    Eur J Cancer; 2012 Feb 21; 48(3):333-9. PubMed ID: 22209391
    [Abstract] [Full Text] [Related]

  • 19. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.
    Tsimafeyeu I, Snegovoy A, Varlamov S, Safina S, Varlamov I, Gurina L, Manzuk L.
    Target Oncol; 2015 Sep 21; 10(3):423-7. PubMed ID: 25466382
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.